OliX完成脱发药OLX104C 1b期随访，计划年内进入2a期

OliX Pharmaceuticals has completed follow-up monitoring of the last patient in a Phase 1b trial of its male pattern hair-loss treatment. The company plans to speed up its analysis of the Phase 1b data and subsequent development, aiming to enter a Phase 2 trial within this year.
OliX said on the 24th that it had completed patient follow-up in the Australian Phase 1b trial of OLX104C, its male pattern hair-loss treatment. The company began dosing the first patient in the combined Phase 1b/2a trial last December, finished dosing all patients last month, and has now completed follow-up monitoring of the final patient.
OliX plans to analyze the safety and tolerability data from the Phase 1b trial and accelerate subsequent clinical development to enter a Phase 2a trial within this year. The Phase 2a trial will move beyond the early stage focused on safety assessment to begin testing in earnest whether OLX104C is effective in humans in patients with male pattern hair loss.
OLX104C is an RNA interference therapy designed to reduce the expression of the androgen receptor (AR), one of the main causes of male pattern hair loss. Male pattern hair loss is a condition in which dihydrotestosterone (DHT), a male hormone, binds to the AR in hair follicle cells, causing hair to gradually thin. Unlike existing oral treatments, which act throughout the body by suppressing DHT production, OLX104C is being developed to be applied topically to the scalp to lower the expression of the AR itself. The goal is to reduce the potential side effects associated with the systemic exposure of existing treatments.
An OliX official said, "OLX104C has completed both patient dosing and follow-up in the Phase 1b trial on the originally planned schedule," adding, "We are picking up the pace of development, aiming to enter the Phase 2a trial and dose the first patient within this year."